{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:54:27Z","timestamp":1780354467135,"version":"3.54.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sociedad M\u00e9dica Andaluza de Adicciones y Patolog\u00edas M\u00e9dicas Asociadas"},{"name":"Consejer\u00eda de Salud y Bienestar Social, Junta de Andaluc\u00eda-Fundaci\u00f3n Progreso y Salud","award":["PI-0140-2018"],"award-info":[{"award-number":["PI-0140-2018"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD19\/00019"],"award-info":[{"award-number":["CD19\/00019"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methadone and buprenorphine are the most prevalent types of opioid maintenance programs in Andalusia. The main objective is comparing the functional status of patients with pharmacological opioid maintenance treatments according to different socio-demographic characteristic, health and disabilities domains and sexual difficulties.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 593 patients from the Andalusia community, 329 were undergoing methadone treatment and 264 were undergoing buprenorphine treatment. The patients were interviewed by socio-demographic and opioid-related variables, assessed by functioning,\n disability and health domains (\n                      <jats:italic>WHODAS 2.0.<\/jats:italic>\n                      ) and for sexual problems (\n                      <jats:italic>PRSexDQ-SALSEX<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found significant differences in the socio-demographic and the opioid-related variables as the onset of opioid use, being on previous maintenance programs, opioid intravenous use, the length of previous maintenance programs, polydrug use and elevated seroprevalence rates (HCV and HIV) between the methadone group and the buprenorphine group. Regarding health and disability domains there were differences in the\n                      <jats:italic>Understanding and communication<\/jats:italic>\n                      domain,\n                      <jats:italic>Getting around<\/jats:italic>\n                      domain,\n                      <jats:italic>Participation in society<\/jats:italic>\n                      domain and in the WHODAS 2.0. simple and complex score, favoring buprenorphine-treated patients. The methadone group referred elevated sexual impairments compared with the buprenorphine group. Opioid-related variables as seroprevalence rates, other previous lifetime maintenance program, the daily opioid dosage and the daily alcohol use are the most discriminative variables between both groups. Participation in society variables and sexual problems were the most important clinical variables in distinguishing the methadone group from the buprenorphine group regarding their functional status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The methadone group showed higher prevalence in opioid dependence-related variables, elevated disabilities in participation in society activities and sexual problems compared with the buprenorphine group. This study shows the importance of carry out a functional evaluation in the healthcare follow-up, especially in those areas related with social activity and with sexual problems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-021-00488-2","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T04:03:48Z","timestamp":1618286628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders"],"prefix":"10.1186","volume":"18","author":[{"name":"The ANDOPIO Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Ru\u00edz Ru\u00edz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Martinez Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-3613","authenticated-orcid":false,"given":"Nuria","family":"Garc\u00eda-Marchena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"488_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/add.12551","volume":"109","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, et al. The global epidemiology and burden of opioid dependence: results from the Global Burden of Disease 2010 study. Addiction. 2014;109:1320\u201333.","journal-title":"Addiction"},{"key":"488_CR2","volume-title":"European drug report 2019: trends and developments","author":"EMCDDA","year":"2019","unstructured":"EMCDDA. European drug report 2019: trends and developments. Luxembourg: Publications Office of the European Union; 2019."},{"key":"488_CR3","unstructured":"EMCDDA. European Monitoring Centre for Drugs and Drug Addiction. Spain. Country Drug Report 2017. 2017."},{"key":"488_CR4","unstructured":"C\u00aaIyPS, Consejer\u00eda de Igualdad y Pol\u00edticas Sociales. Indicador admisiones a tratamiento por abuso o dependencia a sustancias o por adicciones comportamentales en Andaluc\u00eda. 2017. Junta de Andaluc\u00eda: Agencia de Servicios Sociales y Dependencia de Andaluc\u00eda; 2018."},{"key":"488_CR5","unstructured":"C\u00aaIyPS, Consejer\u00eda de Igualdad y Pol\u00edticas Sociales. \u00c1rea de Drogodependencias y Adicciones. Memoria 2016. Junta de Andaluc\u00eda: Secretar\u00eda General de Servicios Sociales; 2016."},{"issue":"8","key":"488_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","volume":"193","author":"VP Dole","year":"1965","unstructured":"Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA. 1965;193(8):646\u201350.","journal-title":"JAMA"},{"issue":"2\u20133","key":"488_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/10550887.2015.1059225","volume":"34","author":"DM Novick","year":"2015","unstructured":"Novick DM, et al. Methadone medical maintenance: an early 21st-century perspective. J Addict Dis. 2015;34(2\u20133):226\u201337.","journal-title":"J Addict Dis"},{"issue":"3","key":"488_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2165\/00003088-197601030-00004","volume":"1","author":"BA Berkowitz","year":"1976","unstructured":"Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976;1(3):219\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"488_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/01.jcp.0000178417.60426.60","volume":"25","author":"M Soyka","year":"2005","unstructured":"Soyka M, et al. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol. 2005;25(5):490\u20133.","journal-title":"J Clin Psychopharmacol"},{"issue":"9358","key":"488_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","volume":"361","author":"J Kakko","year":"2003","unstructured":"Kakko J, et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662\u20138.","journal-title":"Lancet"},{"issue":"1","key":"488_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.18553\/jmcp.2010.16.S1-B.14","volume":"16","author":"L Nicholls","year":"2010","unstructured":"Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm. 2010;16(1):14\u201321.","journal-title":"J Manag Care Pharm"},{"issue":"9","key":"488_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2017.0001","volume":"317","author":"S Nielsen","year":"2017","unstructured":"Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA. 2017;317(9):967\u20138.","journal-title":"JAMA"},{"issue":"13","key":"488_CR13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","volume":"284","author":"AT McLellan","year":"2000","unstructured":"McLellan AT, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689\u201395.","journal-title":"JAMA"},{"issue":"6","key":"488_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1360-0443.1997.tb02937.x","volume":"92","author":"M Torrens","year":"1997","unstructured":"Torrens M, et al. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction. 1997;92(6):707\u201316.","journal-title":"Addiction"},{"key":"488_CR15","doi-asserted-by":"publisher","first-page":"c5475","DOI":"10.1136\/bmj.c5475","volume":"341","author":"R Cornish","year":"2010","unstructured":"Cornish R, et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010;341:c5475.","journal-title":"BMJ"},{"key":"488_CR16","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"issue":"3","key":"488_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1360-0443.1996.tb02289.x","volume":"91","author":"S Darke","year":"1996","unstructured":"Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction. 1996;91(3):405\u201311.","journal-title":"Addiction"},{"key":"488_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0140-6736(98)05356-2","volume":"353","author":"J Ward","year":"1999","unstructured":"Ward J, Hall W, Mattick R. Role of methadone maintenance in opioid dependence. Lancet. 1999;353:221\u20136.","journal-title":"Lancet"},{"issue":"9","key":"488_CR19","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","volume":"103","author":"P Lawrinson","year":"2008","unstructured":"Lawrinson P, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS. Addiction. 2008;103(9):1484\u201392.","journal-title":"Addiction"},{"issue":"1","key":"488_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1532-5415.2010.03210.x","volume":"59","author":"JH Van Cleave","year":"2011","unstructured":"Van Cleave JH, Egleston BL, McCorkle R. Factors affecting recovery of functional status in older adults after cancer surgery. J Am Geriatr Soc. 2011;59(1):34\u201343.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"488_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/00006199-199407000-00002","volume":"43","author":"NK Leidy","year":"1994","unstructured":"Leidy NK. Functional status and the forward progress of merry-go-rounds: toward a coherent analytical framework. Nurs Res. 1994;43(4):196\u2013202.","journal-title":"Nurs Res"},{"issue":"6","key":"488_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/(SICI)1098-240X(199612)19:6<485::AID-NUR4>3.0.CO;2-K","volume":"19","author":"MA Rowe","year":"1996","unstructured":"Rowe MA. The impact of internal and external resources on functional outcomes in chronic illness. Res Nurs Health. 1996;19(6):485\u201397.","journal-title":"Res Nurs Health"},{"issue":"1","key":"488_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1360-0443.1996.tb03160.x","volume":"91","author":"CF Ryan","year":"1996","unstructured":"Ryan CF, White JM. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction. 1996;91(1):39\u201345.","journal-title":"Addiction"},{"issue":"6","key":"488_CR24","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/j.bja.2018.09.019","volume":"122","author":"C Higgins","year":"2019","unstructured":"Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth. 2019;122(6):e114\u201326.","journal-title":"Br J Anaesth"},{"key":"488_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.psychres.2016.06.024","volume":"243","author":"C Roncero","year":"2016","unstructured":"Roncero C, et al. Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: the PROTEUS study. Psychiatry Res. 2016;243:174\u201381.","journal-title":"Psychiatry Res"},{"issue":"Suppl 1","key":"488_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1360-0443.2006.01592.x","volume":"101","author":"MA Schuckit","year":"2006","unstructured":"Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction. 2006;101(Suppl 1):76\u201388.","journal-title":"Addiction"},{"issue":"1\u20133","key":"488_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drugalcdep.2012.06.020","volume":"127","author":"JD Savant","year":"2013","unstructured":"Savant JD, et al. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine\/naloxone treatment. Drug Alcohol Depend. 2013;127(1\u20133):243\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"488_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajp.2016.06.017","volume":"23","author":"N Aggarwal","year":"2016","unstructured":"Aggarwal N, et al. A study of assessment of sexual dysfunction in male subjects with opioid dependence. Asian J Psychiatr. 2016;23:17\u201323.","journal-title":"Asian J Psychiatr"},{"issue":"1","key":"488_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/ADM.0000000000000267","volume":"11","author":"JB Teoh","year":"2017","unstructured":"Teoh JB, et al. Erectile dysfunction among patients on methadone maintenance therapy and its association with quality of life. J Addict Med. 2017;11(1):40\u20136.","journal-title":"J Addict Med"},{"issue":"3","key":"488_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/jcm8030321","volume":"8","author":"C Llanes","year":"2019","unstructured":"Llanes C, et al. Sexual dysfunction and quality of life in chronic heroin-dependent individuals on methadone maintenance treatment. J Clin Med. 2019;8(3):321.","journal-title":"J Clin Med"},{"key":"488_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.drugalcdep.2013.10.011","volume":"134","author":"JP Feelemyer","year":"2014","unstructured":"Feelemyer JP, et al. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review. Drug Alcohol Depend. 2014;134:251\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"488_CR32","volume-title":"Diagnostic criteria from dsM-iV-tr","author":"AP Association","year":"2000","unstructured":"Association AP. Diagnostic criteria from dsM-iV-tr. American Psychiatric Pub; 2000."},{"key":"488_CR33","volume-title":"Measuring health and disability: Manual for WHO disability assessment schedule WHODAS 2.0","author":"TB \u00dcst\u00fcn","year":"2010","unstructured":"\u00dcst\u00fcn TB, et al. Measuring health and disability: Manual for WHO disability assessment schedule WHODAS 2.0. World Health Organization; 2010."},{"key":"488_CR34","volume-title":"International classification of functioning, disability and health (ICF)","author":"World Health Organization","year":"2001","unstructured":"World Health Organization. International classification of functioning, disability and health (ICF). World Health Organization; 2001."},{"issue":"23","key":"488_CR35","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1080\/09638288.2016.1223177","volume":"39","author":"S Federici","year":"2017","unstructured":"Federici S, et al. World Health Organization disability assessment schedule 2.0: an international systematic review. Disabil Rehabil. 2017;39(23):2347\u201380.","journal-title":"Disabil Rehabil"},{"key":"488_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1477-7525-8-51","volume":"8","author":"O Garin","year":"2010","unstructured":"Garin O, et al. Validation of the \u201cWorld Health Organization Disability Assessment Schedule, WHODAS-2\u201d in patients with chronic diseases. Health Qual Life Outcomes. 2010;8:51.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"488_CR37","first-page":"77","volume":"28","author":"JL V\u00e1zquez-Barquero","year":"2000","unstructured":"V\u00e1zquez-Barquero JL, et al. Spanish version of the new World Health Organization Disability Assessment Schedule II (WHO-DAS-II): initial phase of development and pilot study. Cantabria disability work group. Actas Esp Psiquiatr. 2000;28(2):77\u201387.","journal-title":"Actas Esp Psiquiatr"},{"issue":"2","key":"488_CR38","first-page":"77","volume":"28","author":"J V\u00e1zquez-Barquero","year":"2000","unstructured":"V\u00e1zquez-Barquero J, et al. Spanish version of the new World Health Organization Disability Assessment Schedule II (WHO-DAS-II): initial phase of development and pilot study. Cantabria disability work group. Actas Espanolas de Psiquiatria. 2000;28(2):77\u201387.","journal-title":"Actas Espanolas de Psiquiatria"},{"issue":"3","key":"488_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/00926230701866125","volume":"34","author":"\u00c1L Montejo","year":"2008","unstructured":"Montejo \u00c1L, Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther. 2008;34(3):227\u201339.","journal-title":"J Sex Marital Ther"},{"issue":"1","key":"488_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0376-8716(99)00011-3","volume":"56","author":"A Domingo-Salvany","year":"1999","unstructured":"Domingo-Salvany A, et al. Methadone treatment in Spain, 1994. Drug Alcohol Depend. 1999;56(1):61\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"488_CR41","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1081\/JA-120039392","volume":"39","author":"E Puigdollers","year":"2004","unstructured":"Puigdollers E, et al. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse. 2004;39(9):1353\u201368.","journal-title":"Subst Use Misuse"},{"issue":"11","key":"488_CR42","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.3390\/ijerph6112822","volume":"6","author":"M Astals","year":"2009","unstructured":"Astals M, et al. Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. Int J Environ Res Public Health. 2009;6(11):2822\u201332.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"488_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.20882\/adicciones.241","volume":"21","author":"AM Fern\u00e1ndez Sobrino","year":"2009","unstructured":"Fern\u00e1ndez Sobrino AM, Fern\u00e1ndez Rodr\u00edguez V, L\u00f3pez Castro J. Benzodiazepine use in a sample of patients on a treatment program with opiate derivatives (PTDO). Adicciones. 2009;21(2):143\u20136.","journal-title":"Adicciones"},{"key":"488_CR44","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/j.bja.2018.09.019","volume":"122","author":"C Higgins","year":"2018","unstructured":"Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth. 2018;122:e114.","journal-title":"Br J Anaesth"},{"key":"488_CR45","doi-asserted-by":"crossref","unstructured":"Connock M, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. In: NIHR Health Technology Assessment programme: executive summaries. NIHR Journals Library; 2007.","DOI":"10.3310\/hta11090"},{"key":"488_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.neubiorev.2016.11.008","volume":"73","author":"A Baldacchino","year":"2017","unstructured":"Baldacchino A, et al. Neuropsychological functioning and chronic methadone use: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2017;73:23\u201338.","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"488_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/10826084.2017.1400068","volume":"53","author":"JS Woods","year":"2018","unstructured":"Woods JS, Joseph H. From narcotic to normalizer: the misperception of methadone treatment and the persistence of prejudice and bias. Subst Use Misuse. 2018;53(2):323\u20139.","journal-title":"Subst Use Misuse"},{"issue":"4","key":"488_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1300\/J069v21n04_05","volume":"21","author":"HW Daniell","year":"2002","unstructured":"Daniell HW. Narcotic-induced hypogonadism during therapy for heroin addiction. J Addict Dis. 2002;21(4):47\u201353.","journal-title":"J Addict Dis"},{"issue":"2","key":"488_CR49","doi-asserted-by":"publisher","first-page":"e88289","DOI":"10.1371\/journal.pone.0088289","volume":"9","author":"M Zhang","year":"2014","unstructured":"Zhang M, et al. Sexual dysfunction improved in heroin-dependent men after methadone maintenance treatment in Tianjin, China. PLoS ONE. 2014;9(2):e88289.","journal-title":"PLoS ONE"},{"issue":"2","key":"488_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1300\/J069v24n02_08","volume":"24","author":"R Brown","year":"2005","unstructured":"Brown R, et al. Methadone maintenance and male sexual dysfunction. J Addict Dis. 2005;24(2):91\u2013106.","journal-title":"J Addict Dis"},{"issue":"1","key":"488_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jsm.12352","volume":"11","author":"A Yee","year":"2014","unstructured":"Yee A, Loh HS, Ng CG. The prevalence of sexual dysfunction among male patients on methadone and buprenorphine treatments: a meta-analysis study. J Sex Med. 2014;11(1):22\u201332.","journal-title":"J Sex Med"},{"key":"488_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40360-016-0058-9","volume":"17","author":"S Walcher","year":"2016","unstructured":"Walcher S, et al. The opiate dosage adequacy scale for identification of the right methadone dose\u2014a prospective cohort study. BMC Pharmacol Toxicol. 2016;17:15.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"11","key":"488_CR53","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3109\/10826089209047354","volume":"27","author":"WD Spring Jr","year":"1992","unstructured":"Spring WD Jr, Willenbring ML, Maddux TL. Sexual dysfunction and psychological distress in methadone maintenance. Int J Addict. 1992;27(11):1325\u201334.","journal-title":"Int J Addict"},{"key":"488_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1747-597X-9-13","volume":"9","author":"J Reimer","year":"2014","unstructured":"Reimer J, et al. When higher doses in opioid replacement treatment are still inadequate\u2014association to multidimensional illness severity: a cohort study. Subst Abuse Treat Prev Policy. 2014;9:13.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"488_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1210\/jc.2004-0929","volume":"90","author":"N Bliesener","year":"2005","unstructured":"Bliesener N, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"488_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/0972-6748.160930","volume":"24","author":"S Ramdurg","year":"2015","unstructured":"Ramdurg S, Ambekar A, Lal R. Co-relationship between sexual dysfunction and high-risk sexual behavior in patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence. Ind Psychiatry J. 2015;24(1):29\u201334.","journal-title":"Ind Psychiatry J"},{"issue":"3","key":"488_CR57","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/00002508-200205000-00002","volume":"18","author":"LJ Roberts","year":"2002","unstructured":"Roberts LJ, et al. Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain. 2002;18(3):144\u20138.","journal-title":"Clin J Pain"},{"issue":"11","key":"488_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4236\/pp.2018.911036","volume":"09","author":"S Nalamachu","year":"2018","unstructured":"Nalamachu S, et al. Hormone replacement therapy for restoring the HPG axis in pain patients treated with long-term opioid analgesics. Pharmacol Pharm. 2018;09(11):8.","journal-title":"Pharmacol Pharm"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00488-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00488-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T04:09:39Z","timestamp":1618286979000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00488-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00488-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-47994\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, the privacy and confidentially of the protocols and recruitment were approved by the plenary of the Research Ethics Committee of our institution (<i>Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n Provincial de M\u00e1laga del 27 de abril de 2017<\/i>) and conducted according to the guidelines instated by the Ethical Principles for Medical Research Involving Human Subjects adopted in the Declaration of Helsinki by the World Medical Association (64th WMA General Assembly, Fortaleza, Brazil, October 2013), Recommendation No. R (97) 5 of the Committee of Ministers to Member States on the Protection of Medical Data (1997), and European data protection act (Ley Org\u00e1nica del Parlamento Europeo y del Consejo de 27 de abril de 2016 de Protecci\u00f3n de Datos, RGDP). All collected data were assigned numerical codes for privacy and confidentiality. Written informed consent was obtained from all patients in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}